Action of Shiga toxin type-2 and Subtilase cytotoxin on human microvascular endothelial cells by Amaral, María Marta et al.
Action of Shiga Toxin Type-2 and Subtilase Cytotoxin on
Human Microvascular Endothelial Cells
María M. Amaral1*, Flavia Sacerdoti1, Carolina Jancic2, Horacio A. Repetto3, Adrienne W. Paton4, James
C. Paton4, Cristina Ibarra1
1 Laboratorio de Fisiopatogenia, Departamento de Fisiología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina, 2 Laboratorio de
Inmunidad Innata, Instituto de Medicina Experimental (IMEX-CONICET), Academia Nacional de Medicina, Buenos Aires, Argentina, 3 Servicio de Pediatría,
Hospital Nacional Profesor Alejandro Posadas, Buenos Aires, Argentina, 4 Research Centre for Infectious Diseases, School of Molecular and Biomedical
Science, University of Adelaide, Adelaide, Australia
Abstract
The hemolytic uremic syndrome (HUS) associated with diarrhea is a complication of Shiga toxin (Stx)-producing
Escherichia coli (STEC) infection. In Argentina, HUS is endemic and responsible for acute and chronic renal failure in
children younger than 5 years old. The human kidney is the most affected organ due to the presence of very Stx-
sensitive cells, such as microvascular endothelial cells. Recently, Subtilase cytotoxin (SubAB) was proposed as a
new toxin that may contribute to HUS pathogenesis, although its action on human glomerular endothelial cells
(HGEC) has not been described yet. In this study, we compared the effects of SubAB with those caused by Stx2 on
primary cultures of HGEC isolated from fragments of human pediatric renal cortex. HGEC were characterized as
endothelial since they expressed von Willebrand factor (VWF) and platelet/endothelial cell adhesion molecule 1
(PECAM-1). HGEC also expressed the globotriaosylceramide (Gb3) receptor for Stx2. Both, Stx2 and SubAB
induced swelling and detachment of HGEC and the consequent decrease in cell viability in a time-dependent
manner. Preincubation of HGEC with C-9 −a competitive inhibitor of Gb3 synthesis-protected HGEC from Stx2 but
not from SubAB cytotoxic effects. Stx2 increased apoptosis in a time-dependent manner while SubAB increased
apoptosis at 4 and 6 h but decreased at 24 h. The apoptosis induced by SubAB relative to Stx2 was higher at 4 and
6 h, but lower at 24 h. Furthermore, necrosis caused by Stx2 was significantly higher than that induced by SubAB at
all the time points evaluated. Our data provide evidence for the first time how SubAB could cooperate with the
development of endothelial damage characteristic of HUS pathogenesis.
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Introduction
Hemolytic uremic syndrome (HUS) is characterized by non-
immune hemolytic anemia, thrombocytopenia and acute renal
failure [1]. The classical form of HUS is a complication of Shiga
toxin (Stx)-producing Escherichia coli (STEC) infection, the
most prevalent infectious agent responsible for the
development of this pathology [2].
In Argentina, HUS is endemic with a high incidence of more
than 500 cases per year, being the most common cause of
acute renal failure and the second leading cause of chronic
renal failure in children younger than 5 years old [3,4].
Clinical and histological renal damage has been strongly
associated with Stx types 1 and 2 (Stx1, Stx2) produced by
O157:H7 STEC, although strains that only express Stx2 are
highly prevalent in Argentina [5]. However, other non-O157:H7
serotypes have been shown to cause HUS [6].
STEC are present in the intestinal tract of healthy cattle and
disease outbreaks are frequently due to ingestion of
undercooked ground beef, manure-contaminated water,
vegetables, fruit or unpasteurized milk.
After bacteria colonize the bowel, Stx is released into the gut
lumen and then absorbed into the circulation, where the toxin
reaches vascular endothelial cells and finally binds its specific
receptor, the globotriaosylceramide (Gb3) [7]. This receptor is
located on the plasma membrane of target cells, particularly
microvascular endothelial cells present in the kidneys [8], brain
and other organs. Nevertheless the human kidney is the most
affected organ in diarrhea-associated HUS, the likely reason
being the presence of very Stx-sensitive cells which express
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high amounts of biologically active Stx receptor [9]. Indeed,
human microvascular endothelial cells express 50-fold higher
Gb3 levels than endothelial cells derived from large vessels
[10]. Another reason is that the high volume of blood flow and
filtration rate increase the chance of Stx interaction with cells of
the renal microvasculature and the filtration barrier [9].
Endothelial dysfunction is essential to the development of
microvascular lesions in HUS [11,12] and it is well known that
Stx is able to increase and expand kidney injury through
favoring interactions between the endothelium and leukocytes
[13] and platelets [14]. The characteristic lesion of HUS,
thrombotic microangiopathy, consists of thickening of arterioles
and capillaries, swelling and detachment of endothelial cells
from the basement membrane, and platelet thrombi that
obstruct the microcirculation of different organs, predominantly
the kidney [15]. This cell damage is induced by different
mechanisms, such as inhibition of protein synthesis and
increases in the protein levels of chemokines, cytokines, and
adhesion molecules [14,16–18]. In addition, Gb3 expression
and Stx toxicity are increased by inflammatory cytokines such
as TNFα, in human glomerular endothelial cells [19].
The concentration of free Stx in serum of patients with HUS
could not be established [2,20] because the toxin binds
different types of cells including erythrocytes [21], platelets [22]
and monocytes [23]. In addition it has been postulated that Stx
circulates bound to polymorphonuclear leukocytes (PMN) [24],
so endothelial cells would be exposed to very small amounts of
free Stx [25]. Recently, Brigotti et al. [26] suggested that the
extent of renal damage in children with HUS could depend on
the amount of Stx presented to their PMN, which could then
deliver the toxin to the renal endothelium.
Several non-O157 STEC strains produce Subtilase cytotoxin
(SubAB), which may contribute to HUS pathogenesis. SubAB
was discovered in a strain of STEC belonging to serotype
O113:H21 that caused an outbreak of HUS in South Australia
[27]; this serotype has also been isolated from children with
HUS in Argentina [28]. SubAB action on eukaryotic cells
involves highly specific A-subunit-mediated proteolytic
cleavage of the endoplasmic reticulum (ER) chaperone BiP
(GRP78) [29]. This triggers a massive ER stress response,
ultimately leading to apoptosis [30–32]. Recently, it was shown
that this toxin increases the tissue factor-dependent factor Xa
generation in cultured human umbilical vein endothelial cells
and human macrophages, suggesting a direct procoagulant
effect [33]. SubAB had a strong preference for binding glycans
terminating in N-glycolylneuraminic acid (Neu5Gc) [34] and this
monosaccharide was postulated as the key component of the
SubAB receptor; NeuGc is not synthesized in humans, but can
be incorporated into human tissues through dietary intake.
Several SubAB-binding proteins containing Neu5Gc were
identified in Vero [35] and HeLa cells [36]. So far, the effects of
SubAB on human glomerular endothelial cells (HGEC) and the
associated mechanism of action have not been described. In
this study we have developed primary cultures of HGEC to




Toxins: Stx2 was provided by Phoenix Laboratory, while
SubAB was purified as described previously [29].
Competitive inhibitor of Gb3 synthesis: C-9 [(1R, 2R)-
nonanoic acid [2-(2’, 3’-dihydro-benzo [1–4]dioxin-6’-yl)-2-
hydroxy-1-pyrrolidin-1-ylmethyl-ethyl]-amide-L-tartaric acid salt]
was from Genzyme Corp., USA.
Cell culture
Human glomerular endothelial cells (HGEC) were isolated
from kidneys removed from different pediatric patients
undergoing nephrectomies performed at Hospital Nacional
“Alejandro Posadas”, Buenos Aires, Argentina (written
informed consent was obtained from the next of kin,
caretakers, or guardians on the behalf of the minors/children
participants involved in our study). The Ethics Committee of the
University of Buenos Aires approved the use of human renal
tissues for research purposes. The method used for glomerular
endothelial cell isolation was adapted from that described by
McGinn et al. [37]. Brieﬂy, segments of macroscopically normal
human renal cortex were minced using a scalpel blade and
enzyme digested using 0.1% collagenase type I in buffer
Hanks Balanced Salt Solution (HBSS) with 0.1% fetal calf
serum (FCS) at 37°C for 30 min. Enzyme digestion was
stopped by the addition of ice cold HBBS containing 5% FCS
and the sample was washed twice with cold HBBS containing
5% FCS. The tissue was filtered through a 70 µm Nylon cell
strainer. The glomeruli were collected on the top of the strainer,
washed with cold HBBS containing 5% FCS and then
incubated with 0.6% collagenase type I in HBSS with 0.1%
FCS at 37°C for 30 min. Finally, the enzyme digestion was
stopped and washed, as described above. The cells were
resuspended in complete medium: M199 medium (Sigma,
USA) supplemented with 20% FCS, 3.2mM L-glutamine, 100
U/ml penicillin/streptomycin (GIBCO, USA) and 25 µg/ml
endothelial cell growth supplement ECGS (Sigma, USA) and
then cultured in 0.2% gelatin (BDH, United Kingdom) coated
ﬂasks. Cells were grown at 37°C in a humidiﬁed 5% CO2
incubator and subcultured at conﬂuence by trypsinization with
0.05% trypsin-0.02% EDTA (GIBCO, USA). For growth-
arrested conditions, a medium with a half of FCS concentration
(10%) and without ECGS was used. At the experiments, cells
were used between 2–7 passages.
Cell characterization
Flow cytometry: Confluent cells were detached by trypsin
and the presence of von Willebrand factor (VWF) was
analyzed. Cells were fixed with 4% paraformaldehyde and
permeabilized with saponin (0.1% in PBS). Then, cells were
incubated with a polyclonal rabbit anti-human VWF (DAKO,
Argentina) in PBS with 0.5% FCS and then stained with a goat
anti-rabbit FITC. The stained cells were washed with saponin
buffer twice. Finally, cells were resuspended in isoflow and
then were acquired (approximately 50,000 events) by a FACS
flow cytometer. In all cases, isotype matched control antibodies
were used, and a gate based on the forward and orthogonal
Stx2 and SubAB action on human microvasculature
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light scatter was defined to exclude cell debris. Analysis was
performed using Cell Quest software (BD Biosciences, USA).
The results are expressed as the mean fluorescence intensity
(MIF) relative to control cells that do not express VWF (Ctrl).
Microscopy: Endothelial cells were morphologically
characterized at conﬂuence by phase contrast microscopy.
Cells were seeded on gelatin coated glass coverslips (12 mm),
then washed with PBS at pH 7.4 and fixed for 2 h at room
temperature with alcohol 96°, stained with hematoxylin–eosin
(H&E) and observed by light microscopy (×200 and ×400,
Zeiss Axiophot, Germany). Toxin-treated cells were previously
incubated with Stx2 (10 ng/ml) or SubAB (3 µg/ml) for 24 h and
then stained with H&E, as described above. Cell counts were
performed on four fields of ×200 magnifications each. Cell area
values were obtained using ImageJ software (National
Institutes of Health, USA).
Platelet/endothelial cell adhesion molecule 1 (PECAM-1)
expression was analyzed by confocal microscopy. HGEC
seeded on gelatin-coated glass coverslips (12 mm) were
washed with PBS at pH 7.4 and fixed with 3%
paraformaldehyde (10 min on ice). Fixed cells were directly
labeled with a mouse monoclonal anti-human CD31 conjugated
with FITC (Sigma, USA). At the optimal antibody
concentrations, no background labeling of the nucleus and
mitochondria was detected (data not shown). Coverslips were
mounted on glass slides using Fluoromount G
Figure 1.  Cells isolated from human pediatric kidneys cortex express characteristic endothelial markers.  HGEC seeded in
gelatin coated glass coverslips and labeled with either a polyclonal rabbit anti-human VWF and then stained with a goat anti-rabbit
FITC or with a FITC-monoclonal mouse anti-human PECAM-1. The expression of these proteins was analyzed by flow cytometry
(A) and confocal microscopy (B), respectively.
doi: 10.1371/journal.pone.0070431.g001
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(SouthernBiotech, USA). Immunofluorescence images were
acquired with a FluoView FV1000 confocal microscope
(Olympus, Japan) using a Plapon ×60 1.42NA oil immersion
objective and images were analyzed using the Olympus FV10-
ASW software.
Neutral red cytotoxicity assay
The neutral red cytotoxicity assay was adapted from
previously described protocols [38]. HGEC were plated in
gelatin coated 96-well plates and grown to confluence in
complete M199 medium. The cells were then washed in PBS at
pH 7.4 and exposed to Stx2 (0.001 ng/ml to 100 ng/ml) or
SubAB (0.15 ng/ml to 1500 ng/ml) in growth-arrested
conditions for 24, 48 and 72 h. For co-treatment assays, cells
were incubated with Stx2 and SubAB together, using the same
concentrations and times studied in the experiments described
with each toxin alone. Then, two hundred microliters of freshly
diluted neutral red in M199 was added to a final concentration
of 10 μg/ml and cells were incubated for an additional 1 h at
37°C in 5% CO2. Cells were then washed with 200μl 1% CaCl2
+ 1% formaldehyde and solubilized in 200 μl 1% acetic acid in
50% ethanol. Absorption in each well was read in an
automated plate spectrophotometer at 540nm. Results were
expressed as neutral red uptake percentage, where 100%
represents control cells incubated under identical conditions
but without toxin treatment. The 50% cytotoxic dose (CD50)
corresponds to the dilution required to kill 50% of cells. To
examine the effect of C-9, cells were incubated in the presence
of C-9 (from 0.05 to 50 µM) per 48 h before the addition of the
toxins. The cells were then incubated with or without 10 ng/ml
Figure 2.  Stx2 and SubAB modify HGEC morphology.  Cells were seeded in glass coverslips, treated or not with 10 ng/ml Stx2
or 3 µg/ml SubAB for 24 h and then stained with H and E. Morphology and number of HGEC was analyzed by light microscopy
(×200 and ×400). The black arrows indicate the morphological changes as cell swelling (thick arrows) and cell elongation (thin
arrows). HGEC areas were measured by using imageJ software. Results are expressed as means ± SEM of three experiments.
One hundred percent represents values of cells control, Stx2 or SubAB vs Ctrl, *P <0.05.
doi: 10.1371/journal.pone.0070431.g002
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of Stx2 or 3 µg/ml of SubAB for additional 24 h. Finally, cell
viability was established by neutral red uptake.
Gb3 expression
Microscopy: Gb3 expression was analyzed by confocal
microscopy. HGEC were seeded on gelatin coated glass
coverslips (12 mm), then washed with PBS at pH 7.4 and fixed
with 3% paraformaldehyde (10 min on ice). Fixed cells were
first incubated overnight with a rat anti-human CD77 (AbD
Serotec, USA) and then with a goat IgM anti-rat conjugated
with FITC, for 2 h. Coverslips were mounted on glass slides
using Fluoromount G. Immunofluorescence images were
acquired with a FluoView FV1000 confocal microscope
(Olympus, Japan) using a Plapon ×60 1.42NA oil immersion
objective and images were analyzed using the Olympus FV10-
ASW software.
Thin-layer chromatography: Gb3 was detected by thin-layer
chromatography (TLC). HGEC were seeded in tissue culture
flasks and grown at 37°C in an atmosphere of 5% CO2 until the
cells were nearly confluent. Adherent cell monolayers were
released from the flask by trypsinization as described above,
collected by centrifugation, and resuspended in PBS at pH 7.4.
Cells were washed twice with PBS at pH 7.4 to deplete the
serum lipids. Total HGEC glycolipids were extracted according
to the method of Bligh and Dyer [39]. Briefly, 3 ml of
chloroform: methanol 2: 1 v/v was added to the cells, and
incubated on ice for 15 min. Two ml of chloroform: water (1:1)
was added to the tube and centrifugated at 3,000 rpm for 5 min
to separate phases. The upper aqueous phase was removed,
Figure 3.  Stx2 and SubAB decrease HGEC viability.  Cells placed in 96-well plates were exposed to 0.001 ng/ml to 100 ng/ml
Stx2 (A) or 0.15 ng/ml to 1500 ng/ml SubAB (B) in growth-arrested conditions for 24, 48 and 72 h. Then, cells were incubated with
neutral red for an additional 1 h at 37 °C in 5% CO2. Absorbance of each well was read at 540 nm. One hundred percent represents
cells incubated under identical conditions but without toxin treatment (Ctrl). Results are expressed as means ± SEM of five
experiments, Stx2 or SubAB vs Ctrl, or 24 h vs 48 h vs 72 h, *P <0.05.
doi: 10.1371/journal.pone.0070431.g003
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and the lower phase was brought to dryness. One ml of
methanol and 0.1 ml of 1.0 M NaOH was added to the dried
residue, and incubated 16 h at 37 °C.
After the addition of 2 ml of chloroform and 0.5 ml water and
separation of the phases, the upper phase was removed. The
lower phase, corresponding to the neutral glycolipid extract,
was brought to dryness and used for Gb3 determination.
Fractionated lipids were subjected to TLC with a silica gel 60
aluminum plate previously activated by incubation 15 min at
100°C, in a glass tank with a mixture of chloroform, methanol,
and water (65:35:8). A purified glycosphingolipid standard (1-2
µg) (Matreya, USA) was also added to the plate for
comparison. After the solvent front reached the top of the plate,
the gel matrix was air dried and treated with a solution of
orcinol, water and sulfuric acid (Acros Organics, USA) to
visualize the separated carbohydrate and glycolipid
components. The densitometric analysis of Gb3 bands was
analyzed by Image Quant 5.0 software.
Analysis of Gb3 content in HGEC by an enzymatic
fluorometric method
Glycolipid extract was dispersed in 100 μl of 0.15 mol/l
acetate buffer at pH 4.5; and sodium taurodeoxycholate
(Sigma, USA) was added to emulsify the glycolipids at a final
concentration of 0.046 mol/l. Gb3 present in the HGEC
glycolipids was hydrolyzed to galactose and lactosylceramide
by the addition of 10 μl of 1 mg/ml agalsidase alfa (Shire HGT,
United Kingdom) and incubation at 37 °C overnight. Agalsidase
alfa is available in a 1 mg/ml solution, and was stored aliquoted
at −20°C until use without significant loss of enzymatic activity.
To quantify the galactose produced by the enzymatic
hydrolysis, 3 mm-filter paper discs were impregnated with the
reaction solution. After drying the paper discs at room
temperature for 4 h, galactose was determined by a modified
enzymatic fluorometric method using galactose
dehydrogenase, diaphorase and resazurine. The results were
expressed as Gb3 µg/1.106 cells [40].
Figure 4.  Gb3 is present on HGEC.  HGEC seeded in glass coverslips were labeled with an anti-human CD77 conjugated with
FITC and visualized by confocal microscopy (×600) (A). Neutral glycolipids extracted from HGEC non-treated (Ctrl) or treated with
C-9 (5 µM) for 48 h were subjected to TLC and visualized with orcinol (B). Gb3 was quantified after hydrolysis to galactose by an
enzymatic fluorometric method and results are expressed as means ± SEM of three experiments, *P<0.05 (C).
doi: 10.1371/journal.pone.0070431.g004
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Analysis of cell death mechanisms induced by toxins
Microscopy: HGEC were seeded on gelatin coated glass
coverslips (12 mm) and then were washed with PBS at pH 7.4.
Cells were exposed to 10 ng/ml Stx2 or 3 µg/ml SubAB in
growth-arrested conditions for 4, 6 and 24 h. After each period
of time, % of necrotic and apoptotic cells were established
morphologically by fluorescence microscopy after staining with
acridine orange/ethidium bromide (1:1, v/v) and a final
concentration of 100 μg/ml [41]. Live cells have normal nuclei
staining which present green chromatin with organized
structures; apoptotic cells contain condensed or fragmented
chromatin (green or orange) and necrotic cells have similar
normal nuclei staining as live cells except the chromatin is
orange instead of green.
Figure 5.  Morphologic changes by Stx2 and SubAB
relative to apoptosis and necrosis.  HGEC seeded in glass
coverslips were exposed or not (Ctrl) to 10 ng/ml Stx2 or 3
µg/ml SubAB in growth-arrested conditions for 4, 6 and 24 h.
After each period of time, % of necrotic and apoptotic cells was
established morphologically by fluorescence microscopy after
staining with acridine orange/ethidium (×200).
doi: 10.1371/journal.pone.0070431.g005
Flow cytometry: Annexin V-FITC/PI double staining assay
was used to quantify necrosis and apoptosis. HGEC were
seeded into gelatin coated six well cell culture microplates,
treated with toxins as described above and subsequently, cells
were trypsinized and washed with PBS at pH 7.4. After that,
cells were resuspended in binding buffer (0.1 M Hepes, 1.4 M
NaCl, 25 mM CaCl2) and FITC-conjugated annexin V and PI
(propidium iodide) were added. The mixture was incubated for
10 min at room temperature, cells (approximately 50,000
events) were acquired by a Partec model PAS III flow
cytometer and data were analyzed by Cyflogic software. The
results were interpreted as follows: negative cells for both PI
and Annexin-V-FITC staining were considered live cells; PI-
negative, Annexin-V-FITC-positive stained cells were
considered in early apoptosis; PI-positive, Annexin-V-FITC-
positive or PI-positive and Annexin V-negative-stained cells
were considered in necrosis.
Data Analysis
Data are presented as mean ± SEM. Plotting and statistical
analysis of data was accomplished using GraphPad Prism 5.0
(GraphPad, USA). Comparisons between values of different
groups were performed using one-way ANOVA. Significance
was determined using Dunnett’s multiple comparison test.
Mann Whitney-test was used for comparison between two
groups. Statistical significance was set at P< 0.05.
Results
Identification of VWF and PECAM- 1 on HGEC
Cells obtained from human renal glomeruli were cultured and
characterized for endothelial phenotype. After the first passage,
confluent cells were detached by trypsin treatment and then
analyzed by flow cytometry and microscopy. More than 95% of
the cells were VWF positive (R1, Figure 1A) when compared to
the negative control (cells without staining). The median
intensity of fluorescence (MIF) was 60 ± 0.3 vs 3 ± 0.2 for VWF
and Ctrl, respectively. In addition, these cells also expressed
PECAM-1, visualized by confocal microscopy in green
fluorescence at cell-cell borders and localized at the plasma
membrane (Figure 1B).
Toxins modified HGEC morphology
Cell morphology was analyzed by phase contrast microscopy
and additional staining with H&E, so HGEC were incubated
under growth-arrested conditions either with Stx2 (10 ng/ml) or
SubAB (3 µg/ml) or without toxins for 24 h. Treatment of HGEC
with Stx2 resulted in a reduction in viable attached cells (70 ±
6%) and the remaining cells showed an increase of the cell
area (90 ± 26%) when compared to control. In addition, SubAB
detached fewer cells than Stx2 (50 ± 2%) and the adherent
cells showed an elongated shape with increase of the cell area
(75 ± 14%) when compared to control, n=3, *P<0.05 (Figure 2).
Stx2 and SubAB action on human microvasculature
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HGEC viability decreased after treatment with Stx2 and
SubAB toxins
The effects of Stx2 and SubAB on HGEC viability were
evaluated at different concentrations and times. A significant
decrease in the viability of cells treated with Stx2 was detected
when HGEC were incubated with increasing toxin
concentrations for 24, 48 and 72 h relative to controls (Figure
3A). Stx2 caused a significant reduction of HGEC viability in a
dose-dependent manner from 0.1 ng/ml to 100 ng/ml at all the
time points evaluated. After 72 h the CD50 was 1 ng/ml (viability
%: 48.3 ± 9.1 vs control n=5, *P<0.05). SubAB showed to be
more cytotoxic at 72 than 48 and 24 h of treatment (Figure 3B,
n=5, *P<0.05). After 72 h, a significantly decrease on HGEC
viability was observed with concentrations from 0.15 ng/ml to
1500 ng/ml. The range of SubAB concentrations (15 to 150
ng/ml) represents approximately 50% cell lethality after 72 h of
incubation. Co-treatment of HGEC with Stx2 and SubAB
showed no significant differences in the effects of cytotoxicity
Table 1. C-9 protects HGEC viability from Stx2 toxic effect




 C-9, 48 h C-9 48 h, SubAB 24 hC-9 48 h, Stx2 24 h 
0 94.0 ± 1.2 77.2 ± 4.5 54.0 ± 1.5 0
0.05 80.1 ± 7.3 75.0 ± 7.2 72.1 ± 4.3* 70
0.5 85.0 ± 3.6 75.2 ± 4.5 87.0 ± 10.0* 100
1 87.5 ± 3.5 73.0 ± 6.3 87.3 ± 7.3* 100
5 83.2 ± 8.6 72.0 ± 7.5 93.0 ± 8.5* 100
*. P<0.05, n 4 [C-9 48h, Stx2 24h] vs Stx2
Figure 6.  Stx2 and SubAB produce death cell through apoptotic mechanisms.  Annexin V-FITC/IP double staining assay was
used to quantify necrosis and apoptosis by a flow cytometer. HGEC were treated with 10 ng/ml Stx2 (A) or 3 µg/ml SubAB (B) and
labeled with annexin V-FITC/IP for 10 min. Results are expressed as means ± SEM of three experiments. *P<0.05 for necrosis vs
apoptosis. A representative experiment is shown in panel C.
doi: 10.1371/journal.pone.0070431.g006
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compared to those caused by each toxin alone (data not
shown).
Gb3 present on HGEC surface is inhibited by C-9
Taking into account the sensitivity of HGEC to Stx2, the
presence of Gb3 receptor on HGEC was analyzed by
immunofluorescence and TLC. Figure 4A localized Gb3 as a
green halo on the surface membrane; it was not detected in the
nucleus or mitochondria under optimal antibody concentrations.
In addition, neutral glycolipids extracted from HGEC were
subjected to TLC and then visualized with orcinol staining. A
Gb3 commercial standard (1-2 µg) was used as a positive
control. The glycosphingolipids extracted from HGEC
(incubated or not with C-9) showed the same pattern of bands
as Gb3 receptor standard (Figure 4B). However, a qualitative
decrease of Gb3 expression was observed in HGEC treated
with 5 µM C-9 (inhibitor of Gb3 synthesis). To confirm these
results we quantified the Gb3 on HGEC treated and non-
treated with C-9 by an enzymatic fluorometric method after
hydrolysis to galactose. As shown in Figure 4C, 1.106 of HGEC
contained 0.85 ± 0.20 µg of Gb3 and this concentration
decreased after 48 h of C-9 treatment to 0.28 ± 0.15, n=3,
*P<0.05.
C-9 protected HGEC from Stx2 cytotoxic effects
As we demonstrated above, Gb3 receptor is present on
HGEC. As well, we found that C-9, a glucosylceramide
synthase inhibitor, was able to decrease the Gb3 concentration
in these cells. Taking into account these results, we evaluated
the effect of Stx2 (10 ng/ml), or SubAB (3 µg/ml) in HGEC
previously treated or not with different C-9 concentrations (0.05
µM to 50 µM). After 24 h, the cell viability obtained with Stx2
was 54.0 ± 1.3%, n=4, *P<0.05. When cells were pre-incubated
with C-9 for 48 h, followed by Stx2 or SubAB for 24 h, inhibition
of Stx2 but not SubAB effects was significantly attenuated in a
dose-dependent manner (Table 1). C-9 (50 µM) was cytotoxic
after 24 h of treatment (37.0 ± 1.0. vs control, n=4, *P<0.05,
data not shown).
Stx2 and SubAB induced necrosis and apoptosis on
HGEC
We then studied the mechanisms of cell death induced by
both toxins on HGEC using fluorescence microscopy to
analyze cells stained with acridine orange/ethidium bromide
and flow cytometry for cells labeled with Annexin V-FITC/IP
double staining. The morphologic analysis showed that both
toxins increased the apoptosis and necrosis on HGEC. Figure
5 shows apoptosis by condensed chromatin (green and
orange) and necrosis by orange chromatin. The results
obtained by flow cytometry analysis (Figure 6 A and B) indicate
that Stx2 (10 ng/ml) and SubAB (3 µg/ml) caused more
apoptosis than necrosis at all times considered (4, 6 and 24 h,
n=3; *P<0.05). While Stx2 increased apoptosis in a time-
dependent manner, SubAB increased apoptosis at 4 and 6 h
but decreased at 24 h. The apoptosis induced by SubAB was
higher than Stx2 at 4 and 6 h (4 h: 7.1 ± 0.3 vs 3.2 ± 0.3; 6 h:
7.0 ± 0.7 vs 3.6 ± 0.3, SubAB vs Stx2, n=3, *P<0.05), but lower
than Stx2 at 24 h (3.5 ± 0.5 vs 16.5 ± 0.74, n=3, *P<0.05).
Furthermore, necrosis caused by Stx2 was significantly higher
than that induced by SubAB at 24 h. Figure 6C shows a
representative experiment.
Discussion
Primary cultures of human glomerular microvascular
endothelial cells are very useful for studying the involvement of
toxins that lead to renal failure in HUS. Renal damage has
been associated with Stx1 and Stx2, which promote a pro-
thrombotic phenotype with lesions in the microvessels in
glomeruli [42]. Recently a new toxin, SubAB, has been
described that may be involved in HUS pathogenesis [29,43].
In this work, the effects of Stx2 and SubAB on primary cultures
of HGEC have been compared. These cells were characterized
as endothelial since they expressed VWF and PECAM-1. Both
toxins affected the morphology and viability of HGEC after 24
h. This interaction between HGEC and Stx2 or SubAB triggers
swelling and endothelial detachment that is coincident with the
pathological description of endothelial damage in HUS [44,45].
It is known that endothelial cell viability is dependent on
attachment to basement membrane [46]. In consequence, the
decrease of HGEC cell viability may be the result of such
detachment.
Stx2 but not SubAB reduced HGEC viability in a dose-
dependent manner; this could be a consequence of differential
toxin receptor distribution and/or density, or other intracellular
responses. Our studies have shown that HGEC express Gb3
and the pre-treatment with C-9 protected the cells against Stx2
toxicity. However C-9 did not protect the viability of HGEC from
SubAB effects because this toxin binds glycans terminating in
Neu5Gc, a glycan distinct from Gb3 [34]. . While the inability of
humans to synthesize this monosaccharide has been
described and it is incorporated through food products, the
HGEC susceptibility to SubAB action could be explained by the
presence of these monosaccharides in the FCS [47].
With regard to the intracellular response, apoptosis in
microvascular endothelial cells from human renal glomeruli
caused by Stx has been documented [48] and induction of
apoptosis by SubAB has also been reported for a variety of cell
types, including Vero and HeLa cells [30,36]. To analyze these
mechanisms, we studied necrosis and apoptosis of HGEC
exposed to Stx2 and SubAB. Both toxins caused significantly
more apoptosis than necrosis. While Stx2 increased apoptosis
in a time-dependent manner, SubAB caused apoptosis only at
the shorter treatment times. This result may be due to the two
toxins triggering apoptosis by different routes: Stx2 causes
apoptosis following protein synthesis inhibition which in turn
leads to ER stress, while SubAB causes apoptosis as a
consequence of massive ER stress triggered by the cleavage
of BIP [32,49].
Relevant to the above in vitro data can be the observation
that the damage in endothelial cells is amplified in the presence
of inflammatory factors such as TNF-α [19] which can be
release from monocytes/macrophages in response to Stx [23].
Also relevant may be the potential role of erythrocytes in the
development of the microvascular lesion of HUS. It is assumed
that the presence of fragmented erythrocytes during HUS is
Stx2 and SubAB action on human microvasculature
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consequence of mechanical fragmentation of these cells while
passing through partially occluded capillaries [48]. One study
also reported that erythrocyte membranes were affected by
oxidative damage during HUS [50], leading to eryptosis [51].
Eryptosis may increase erythrocyte adhesion to vascular
endothelium [52] and promote the release of pro-inflammatory
cytokines [53] contributing to the thrombotic cascade initiated
by Stx direct binding to endothelial cells.
In summary, Stx2 and SubAB were capable of decreasing
HGEC viability by endothelial injury similar to that documented
in biopsies of HUS patient kidneys. While Stx2 injury appears
to be mediated by its specific receptor, Gb3, as evidenced by
the inhibitory effects of the Gb3 synthesis inhibitor C-9, SubAB
interacts with distinct glycan structures [36], and hence is
unaffected by the drug. Our findings suggest for the first time
that SubAB cytotoxin can contribute to HUS through HGEC
damage characterized by swelling, detachment and finally
decrease of cellular viability. In this regard, apoptosis appears
to be one of the mechanisms by which this emerging cytotoxin
triggers HGEC death.
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